Works matching AU Takako Inoue


Results: 63
    1
    2
    3

    Outcome of nucleos(t)ide analog cessation in patients with treatment for prevention of or against hepatitis B virus reactivation.

    Published in:
    Hepatology Research, 2023, v. 53, n. 4, p. 289, doi. 10.1111/hepr.13864
    By:
    • Suzuki, Takanori;
    • Matsuura, Kentaro;
    • Urakabe, Kenji;
    • Okumura, Fumihiro;
    • Kawamura, Hayato;
    • Sobue, Satoshi;
    • Matoya, Sho;
    • Miyaki, Tomokatsu;
    • Kimura, Yoshihide;
    • Kato, Daisuke;
    • Kusakabe, Atsunori;
    • Tanaka, Yoshito;
    • Ozasa, Atsushi;
    • Nagura, Yoshihito;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke;
    • Hagiwara, Shinya;
    • Kusumoto, Shigeru;
    • Inoue, Takako;
    • Tanaka, Yasuhito
    Publication type:
    Article
    4
    5
    6

    Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis.

    Published in:
    Hepatology Research, 2020, v. 50, n. 7, p. 840, doi. 10.1111/hepr.13509
    By:
    • Furukawa, Masanori;
    • Moriya, Kei;
    • Nakayama, Jiro;
    • Inoue, Takako;
    • Momoda, Rie;
    • Kawaratani, Hideto;
    • Namisaki, Tadashi;
    • Sato, Shinya;
    • Douhara, Akitoshi;
    • Kaji, Kosuke;
    • Kitade, Mitsuteru;
    • Shimozato, Naotaka;
    • Sawada, Yasuhiko;
    • Saikawa, Soichiro;
    • Takaya, Hiroaki;
    • Kitagawa, Koh;
    • Akahane, Takemi;
    • Mitoro, Akira;
    • Yamao, Junichi;
    • Tanaka, Yasuhito
    Publication type:
    Article
    7
    8
    9
    10
    11
    12
    13
    14

    Clinical application of comprehensive genomic profiling panel to thoracic malignancies: A single‐center retrospective study.

    Published in:
    Thoracic Cancer, 2022, v. 13, n. 21, p. 2970, doi. 10.1111/1759-7714.14643
    By:
    • Kunimasa, Kei;
    • Sugimoto, Naotoshi;
    • Kawamura, Takahisa;
    • Yamasaki, Tomoyuki;
    • Honma, Keiichiro;
    • Nagata, Shigenori;
    • Kukita, Yoji;
    • Fujisawa, Fumie;
    • Inoue, Tazuko;
    • Yamaguchi, Yuko;
    • Kitasaka, Mitsuko;
    • Wakamatsu, Toru;
    • Yamai, Takuo;
    • Yamamoto, Sachiko;
    • Hayashi, Takuji;
    • Inoue, Takako;
    • Tamiya, Motohiro;
    • Imamura, Fumio;
    • Nishimura, Kazuo;
    • Nishino, Kazumi
    Publication type:
    Article
    15
    16
    17
    18

    Gut Dysbiosis Associated With Hepatitis C Virus Infection.

    Published in:
    Clinical Infectious Diseases, 2018, v. 67, n. 6, p. 869, doi. 10.1093/cid/ciy205
    By:
    • Inoue, Takako;
    • Nakayama, Jiro;
    • Moriya, Kei;
    • Kawaratani, Hideto;
    • Momoda, Rie;
    • Ito, Kiyoaki;
    • Iio, Etsuko;
    • Nojiri, Shunsuke;
    • Fujiwara, Kei;
    • Yoneda, Masashi
    Publication type:
    Article
    19
    20
    21

    Bile acid dysmetabolism in the gut‐microbiota‐liver axis under hepatitis C virus infection.

    Published in:
    Liver International, 2022, v. 42, n. 1, p. 124, doi. 10.1111/liv.15041
    By:
    • Inoue, Takako;
    • Funatsu, Yui;
    • Ohnishi, Masaya;
    • Isogawa, Masanori;
    • Kawashima, Keigo;
    • Tanaka, Masaru;
    • Moriya, Kei;
    • Kawaratani, Hideto;
    • Momoda, Rie;
    • Iio, Etsuko;
    • Nakagawa, Hidewaki;
    • Suzuki, Yutaka;
    • Matsuura, Kentaro;
    • Fujiwara, Kei;
    • Nakajima, Atsushi;
    • Yoshiji, Hitoshi;
    • Nakayama, Jiro;
    • Tanaka, Yasuhito
    Publication type:
    Article
    22
    23
    24

    Impact of in vitro chemosensitivity test-guided platinum-based adjuvant chemotherapy on the surgical outcomes of patients with p-stage IIIA non-small cell lung cancer that underwent complete resection.

    Published in:
    Molecular & Clinical Oncology, 2017, v. 7, n. 3, p. 327, doi. 10.3892/mco.2017.1340
    By:
    • YUKI AKAZAWA;
    • MASAHIKO HIGASHIYAMA;
    • KAZUMI NISHINO;
    • JYUNJI UCHIDA;
    • TORU KUMAGAI;
    • TAKAKO INOUE;
    • AYAKO FUJIWARA;
    • TOSHITERU TOKUNAGA;
    • JIRO OKAMI;
    • FUMIO IMAMURA;
    • KEN KODAMA;
    • HISAYUKI KOBAYASHI
    Publication type:
    Article
    25
    26
    27

    Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapies.

    Published in:
    International Journal of Cancer, 2024, v. 154, n. 1, p. 169, doi. 10.1002/ijc.34700
    By:
    • Kemmotsu, Naoya;
    • Ninomiya, Kiichiro;
    • Kunimasa, Kei;
    • Ishino, Takamasa;
    • Nagasaki, Joji;
    • Otani, Yoshihiro;
    • Michiue, Hiroyuki;
    • Ichihara, Eiki;
    • Ohashi, Kadoaki;
    • Inoue, Takako;
    • Tamiya, Motohiro;
    • Sakai, Kazuko;
    • Ueda, Youki;
    • Dansako, Hiromichi;
    • Nishio, Kazuto;
    • Kiura, Katsuyuki;
    • Date, Isao;
    • Togashi, Yosuke
    Publication type:
    Article
    28
    29
    30

    Long‐term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.

    Published in:
    Cancer Science, 2024, v. 115, n. 4, p. 1296, doi. 10.1111/cas.16107
    By:
    • Morise, Masahiro;
    • Kato, Terufumi;
    • Matsumoto, Shingo;
    • Inoue, Takako;
    • Sakamoto, Tomohiro;
    • Tokito, Takaaki;
    • Atagi, Shinji;
    • Kozuki, Toshiyuki;
    • Takeoka, Hiroaki;
    • Chikamori, Kenichi;
    • Shinagawa, Naofumi;
    • Tanaka, Hiroshi;
    • Horii, Eisuke;
    • Adrian, Svenja;
    • Bruns, Rolf;
    • Johne, Andreas;
    • Paik, Paul K.;
    • Sakai, Hiroshi
    Publication type:
    Article
    31
    32
    33
    34
    35
    36
    37

    Prevalence and characteristics of immune checkpoint inhibitor-related myocardial damage: A prospective observational study.

    Published in:
    PLoS ONE, 2022, v. 17, n. 11, p. 1, doi. 10.1371/journal.pone.0275865
    By:
    • Nishikawa, Tatsuya;
    • Inoue, Takako;
    • Otsuka, Tomoyuki;
    • Kuno, Ikumi;
    • Kukita, Yoji;
    • Nakamura, Harumi;
    • Ikeda, Yoshihiko;
    • Yasui, Taku;
    • Shioyama, Wataru;
    • Oka, Toru;
    • Honma, Keiichirou;
    • Hatakeyama, Kinta;
    • Miyata, Hiroshi;
    • Isei, Taiki;
    • Ishihara, Ryu;
    • Kumagai, Toru;
    • Nishimura, Kazuo;
    • Fujita, Masashi
    Publication type:
    Article
    38

    Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B.

    Published in:
    PLoS ONE, 2022, v. 17, n. 2, p. 1, doi. 10.1371/journal.pone.0263844
    By:
    • Nagura, Yoshihito;
    • Matsuura, Kentaro;
    • Iio, Etsuko;
    • Fujita, Koji;
    • Inoue, Takako;
    • Matsumoto, Akihiro;
    • Tanaka, Eiji;
    • Nishiguchi, Shuhei;
    • Kang, Jong-Hon;
    • Matsui, Takeshi;
    • Enomoto, Masaru;
    • Ikeda, Hiroki;
    • Watanabe, Tsunamasa;
    • Okuse, Chiaki;
    • Tsuge, Masataka;
    • Atsukawa, Masanori;
    • Tateyama, Masakuni;
    • Kataoka, Hiromi;
    • Tanaka, Yasuhito
    Publication type:
    Article
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50